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Coagulation, fibrinolysis, and cell
activation in patients and in shed
mediastinal blood during coronary
artery bypass grafting with a new
heparin-coated surface
To the Editor:
Johnell and colleagues1 recently reported
the improved biocompatibility of a new
heparin-coated surface. They also pre-
sented results after modifications of the an-
ticoagulation protocol. They concluded
that a low dose of systemic heparin might
not be sufficient to maintain the antithrom-
botic activity and that a high dose resulted
in increased blood activation.
The design of the study merits discus-
sion; otherwise, the conclusion might be
misunderstood. In particular, the reduction
of anticoagulation, even combined with a
thromboresistant extracorporeal circuit,
might appear detrimental for patients un-
dergoing cardiopulmonary bypass (CPB).
The basis for a safe low anticoagulation
protocol in combination with heparin-
coated CPB circuits was described by Al-
dea and associates2 in 1998. It includes
many parameters derived from the scien-
tific literature from the 1990s, such as con-
trolled suction with cell-saving devices al-
lowing washing before retransfusion,
limitation of air-blood contact with closed
circuits, specifically adapted anticoagula-
tion through precise heparin and protamine
titration, low prime volume facilitated by
retrograde autologous prime, and normo-
thermia. This tailored approach of CPB,
adopted by our own center, has been found
clinically beneficial3 and is therefore justi-
fied for routine surgical practice. One of the
most important parameters omitted by the
authors in the management of a low hepa-
rinized CPB is the retransfusion of highly
activated blood into the circulation because
cardiotomy suction has been used. The
contact of blood with air or with the surgi-
cal field through the tissue pathway is fol-
lowed by activation of inflammation and
hemostasis disturbances, despite the use of
a significant amount of fluid heparin, which
appears to be an unperfected anticoagulant
for CPB although it is universally used.
When a cell-saving device is used instead
of cardiotomy suction, all the different
markers of blood activation are excluded
and not retransfused into the circulation.
With this approach, it has been proved that
circulating F12 levels do not correlate
with activated clotting time (the lowest ac-
tivated clotting time does not imply the
highest F12) and that a low anticoagulation
protocol is safe for the patient.2 Therefore
some of the results presented by Johnell and
colleagues1 need to be taken with caution.
On the other hand, the study of Johnell
and colleagues1 provides important data
about the detrimental effects of heparin,
which could justify a low anticoagulation
protocol. Evidence of proinflammatory and
procoagulant effects of high-dose heparin
was found, as in previous reports. The re-
duction of heparin dose during CPB with
heparin-coated circuits reduces leukocyte
adhesion on artificial surfaces4 and better
preserves antithrombin III levels.5 In addi-
tion, low anticoagulation requires a low
dose of protamine for titration and reduces
the amount of heparin-protamine com-
plexes known to activate the classic path-
way of complement cascade.
The biocompatibility of new equipment
must be assessed, particularly with respect
to thromboresistance. Johnell and col-
leagues1 successfully demonstrated the re-
duction of contact activation. However, it
is fundamental that the experimental design
respect some principles that have been pre-
viously elucidated when they are expected
to be of major importance in the outcome.
This is particularly true if CPB is managed
with low anticoagulation.
Christophe Baufreton, MD, PhD
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Myogenesis after myocardial stem
cell transplantation
To the Editor:
I read the article of Chedrawy and col-
leagues,1 “Incorporation and Integration of
Implanted Myogenic and Stem Cells Into
Native Myocardial Fibers: Anatomic Basis
for Functional Improvements,” in the Jour-
nal with great interest. Chedrawy and col-
leagues1 described regenerated isogenic
myofebrile grafts injected into nonischemic
normal myocardium. By 4 to 6 weeks, fully
differentiated myocytes could be seen to
interconnect among native cardiomyo-
cytes. The authors attributed this desirable
incorporation to cell-cell electromechanical
junction. However, in a clinical setting
with scar tissue and akinetic ventricular
wall, the microenvironment is not condu-
cive to electromechanical activity to induce
a desirable environment to trigger pheno-
typic changes for transplanted cells. Is it
possible that cytokines, such as transform-
ing growth factor  or insulin growth fac-
tor, generated because of the presence of
macrophage and monocytes, play a role in
the genesis of proliferation and transforma-
tion of new myofibrils?
Syde Taheri, MD
9095 Main St
Suite C
Clarence, NY 14031
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Reply to the Editor:
Dr Taheri made an important point in his
comment, which we probably should have
discussed in our article. However, first I, on
behalf of my coauthors, wish to clarify that
we did not inject “isogenic myofibril
grafts,” which would represent a differen-
tiated anatomic unit of a muscle tissue.
Instead, we transplanted either skeletal
myoblasts, which are immature progenitor
cells, or marrow stromal cells, which con-
tain a pluripotent cell population. Such im-
mature cells are able to migrate and self-
assemble with preexisting supracellular
structure, as we reported.
The hypothesis we postulated to explain
the mechanism of this phenomenon should
indeed predict that those donor cells, if
implanted as an isolated island within a
scar tissue, would lack the microenviron-
ment to allow them to integrate into the
preexisting native myocardial syncytium.
We and others have pointed out that how
such cells surrounded by scar contribute to
the myocardial function, as has been re-
ported experimentally and in some early
clinical trials, remains unclear at present.1
It is of some interest to recall how the
strategy of implanting cells into scar
started. In our studies in the early 1990s,2,3
which were the first attempts to use cell
therapy for myocardial regeneration, we
lacked the tools for cell labeling and thus
created a homogeneous scar induced by
cryoinjury. By implanting myoblasts
within such a scar, we were able to show
that the new myofibers surrounded by the
scar tissue originated from our donor cells.
Because turning noncontractile scar tissue
into potentially contractile muscle tissue is
an intuitively appealing idea, many inves-
tigators in the subsequent studies, both ex-
perimental and clinical, have continued to
use the model of implanting cells within
the scar tissue, even though there has been
no convincing evidence that these isolated
muscle fibers can actually contribute to the
synchronized contractile function of the
myocardium.
In studying the pathophysiologic roles
of marrow stromal cells, it has been shown
that tissue injuries, such as myocardial in-
farction, can send a signal to recruit mar-
row stromal cells from the bone marrow,
which traffic through the bloodstream to
target the infarcted segment of the myocar-
dium. There they undergo milieu-depen-
dent differentiation, expressing a number
of phenotypes.4 We have suggested that
some of these cells that reached the peri-
infarct zone became endothelial and vascu-
lar smooth muscle cells to participate in
vasculogenesis and enhance collateral cir-
culation. Some cells, which reached the
scar tissue through patent collateral ves-
sels, may express a myofibroblastic pheno-
type and participate in scar maturation to
reduce scar expansion and rupture. The
marrow cells in the peri-infarct zone that
are in contact with viable and contracting
host myofibers may differentiate into car-
diomyocytes and integrate into the existing
myofibers as we reported1, and this may
play a role in modulating the postinfarct
remodeling process of the ventricle. Yet
other mechanisms are possible. The neo-
cardiomyocytes, which have received phe-
notypic signals from native cardiomyo-
cytes at the peri-infarct zone, may then
migrate toward the myocardial scar to re-
duce infarct size. Various transforming
growth factors and cytokines coming from
the surrounding cells and extracellular matrix
may also play important roles, as suggested
by Dr Taheri. Clearly, much needs to be
learned, and from such understanding better
clinical strategies to use cell therapy for myo-
cardial injury may yet evolve in the future.
Ray C.-J. Chiu, MD, PhD
Senior author
McGill University
Montreal, Quebec, Canada
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Asymptomatic mitral valve
incompetence: Is there evidence for
surgery?
To the Editor:
The article by David and colleagues1 in the
May 2003 issue of the Journal, “Late Out-
comes of Mitral Valve Repair for Floppy
Valves: Implications for Asymptomatic Pa-
tients,” stirs important unanswered ques-
tions and concerns. The conclusion that
patients with asymptomatic mitral valve in-
competence are candidates for surgery
might be extrapolative yet beneficial—if it
had stemmed from a different study design.
In statistical terms, significance for operat-
ing was clearly established; however, this
was more rhetorical than useful in clinical
practice. The following issues were not
mentioned in the discussion or among the
discussants.
First, asymptomatic simply means no
symptoms. Mitral valve surgery is feasible,
but its benefits to the individual patient
cannot be observed here because of the
confounding variables in the methodology
and results. To the reader, the concept of
cause and effect is paramount to executing
successful cardiovascular epidemiology.
Whereas the scientific sequence of cause
and effect is clear, the application of such a
valid concept in this article leans to the
reverse order. In other words, because sur-
gery in patients without symptoms had a
low morbidity and mortality (cause), it is
recommended to operate for asymptomatic
mitral incompetence (effect). Lowering the
threshold to operate must stem from con-
vincing data, and even if statistically sig-
nificant the clinical indication is neither
relative nor absolute. The patient’s physio-
logic status must the underlying cause for
an operation, and the outcome of the oper-
ation (effect) must treat that cause. In this
article despite the effect being feasible, the
cause is far from a true clinical indication.
The practicing surgeon can be confused
with the paradigm of cause and effect that
appears to argue that the mortality is higher
among patients with symptoms. Drawing
feasibility from such a statistic may intro-
duce a new “fuzzy logic” dimension that
has no order and no cause followed by
effect features.2 This logic results from
many decision-making and problem-solv-
ing tasks that are too complex to be under-
stood quantitatively; however, people suc-
ceed by using knowledge that is imprecise
rather than precise.
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